Literature DB >> 27422701

Soluble hemoglobin scavenger receptor CD163 (sCD163) predicts mortality of community-acquired pneumonia.

Yuzo Suzuki1, Yasunori Enomoto2, Koushi Yokomura3, Hironao Hozumi2, Masato Kono2, Masato Karayama2, Kazuki Furuhashi2, Noriyuki Enomoto2, Tomoyuki Fujisawa2, Yutaro Nakamura2, Naoki Inui2, Takafumi Suda2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27422701     DOI： 10.1016/j.jinf.2016.07.004

Source DB:  PubMed          Journal:  J Infect        ISSN： 0163-4453            Impact factor:   6.072


× No keyword cloud information.
  4 in total

1.  Pathogenic characteristics of pulmonary infection in hospitalized patients with chronic heart failure and diagnostic value of sTREM-1, sCD163, and sTWEAK.

Authors:  Fang Zheng
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 1.088

2.  Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.

Authors:  Yasunori Enomoto; Yuzo Suzuki; Hironao Hozumi; Kazutaka Mori; Masato Kono; Masato Karayama; Kazuki Furuhashi; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Daisuke Suzuki; Noriyoshi Ogawa; Ran Nakashima; Tsuneyo Mimori; Toshihide Iwashita; Takafumi Suda
Journal:  Arthritis Res Ther       Date:  2017-01-19       Impact factor: 5.156

3.  Systemic corticosteroid therapy augments ex vivo release of sCD163 by peripheral blood monocytes of asthmatic patients.

Authors:  Paweł L Bernatowicz; Paweł Golec; Paweł Bielecki; Krzysztof Kowal
Journal:  Postepy Dermatol Alergol       Date:  2020-03-09       Impact factor: 1.837

4.  Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia.

Authors:  Kazuo Tsuchiya; Yuzo Suzuki; Katsuhiro Yoshimura; Hideki Yasui; Masato Karayama; Hironao Hozumi; Kazuki Furuhashi; Noriyuki Enomoto; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Koushi Yokomura; Takafumi Suda
Journal:  Sci Rep       Date:  2019-12-10       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.